Company News: StrikeForce Communications and Makovsky + Co.

Share this article:
Alcon has awarded two accounts to StrikeForce Communications, including global strategic and creative responsibilities for I-Caps, a line of ocular nutrition products aimed at delaying the progress of age related macular degeneration, and for OTC dry eye therapy Systane. The New York-based shop also recently won an assignment for Orexigen Theraeutics' obesity drug, which is under FDA review.

Makovsky + Company has been retained by Neoprobe Corp., for its strategic communications and investor relations program as the Dublin, Ohio-based firm, which makes surgical oncology products, prepares for the commercialization of Lymphoseek and the launch of a RIGS clinical development program.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.